Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials

An out-of-office therapeutic agent indicated for molluscum contagiosum is needed. To assess the efficacy and safety of berdazimer gel, 10.3% (a topical, antiviral, nitric oxide–releasing medication) versus vehicle. Berdazimer gel, 10.3% or vehicle was applied once daily to all molluscum contagiosum lesions for 12 weeks in patients ≥6 months with 3-70 mollusca. Efficacy assessment: complete lesion clearance and partial clearance at week 12. Safety and tolerability assessment: adverse events through week 24 and local skin reactions through week 12. There were 1598 patients enrolled (n = 917 berdazimer, n = 681 vehicle). Berdazimer was superior to vehicle at week 12 in complete clearance rates, 30.0% versus 19.8% (odds ratio, 1.75; 95% CI, 1.38-2.23, P